Cargando…
Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?
Parkinson's is a heterogeneous, complex condition. Stratification of Parkinson's subtypes will be essential to identify those that will benefit most from a cell replacement therapy. Foetal mesencephalic grafts can alleviate motor symptoms in some Parkinson's patients. However, on‐goin...
Autores principales: | Kunath, Tilo, Natalwala, Ammar, Chan, Claire, Chen, Yixi, Stecher, Benjamin, Taylor, Martin, Khan, Sadaquate, Muqit, Miratul M. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492143/ https://www.ncbi.nlm.nih.gov/pubmed/30586214 http://dx.doi.org/10.1111/ejn.14314 |
Ejemplares similares
-
Engineering synucleinopathy‐resistant human dopaminergic neurons by CRISPR‐mediated deletion of the SNCA gene
por: Chen, Yixi, et al.
Publicado: (2018) -
Cell‐based therapy for Parkinson's disease: A journey through decades toward the light side of the Force
por: Parmar, Malin, et al.
Publicado: (2018) -
The prodromes of Parkinson's disease
por: Rees, Richard Nathaniel, et al.
Publicado: (2018) -
Induced pluripotent stem cell‐based modeling of mutant LRRK2‐associated Parkinson's disease
por: Weykopf, Beatrice, et al.
Publicado: (2019) -
PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease
por: Kazlauskaite, Agne, et al.
Publicado: (2015)